The Adjunctive Ventricular Arrhythmia Suppression Trial (AVAST) Pilot

• Status: Completed
• Trial end date: 2013-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn if combination therapy with amiodarone and ranolazine (an approved drug for chest pain) can help prevent arrhythmias.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hartford Hospital
• Collaborator: Gilead Sciences
• Treatments: Amiodarone; Ranolazine

Criteria

Inclusion Criteria:

• Patients with an ICD who were on a stable dose of amiodarone for the past 60 days

Exclusion Criteria:

• Patients with a life expectancy of less than 6 months

• Patients with moderate or severe hepatic impairment (Child-Pugh Classes B or C) or requiring hemodialysis.

• Pregnancy or lactation.

• Treatment with potent CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, indinavir, and saquinavir

• Treatment with CYP3A inducers, including rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort.